Maxim S Slesarev
Overview
Explore the profile of Maxim S Slesarev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Converse A, Krasko M, Rudisch D, Lunaris C, Nisbet A, Slesarev M, et al.
Front Neurosci
. 2024 Oct;
18:1451118.
PMID: 39474461
Introduction: Parkinson disease (PD) is a neurodegenerative condition affecting multiple sensorimotor and cognitive systems. The rat model exhibits vocal, cognitive, and limb use deficits seen in idiopathic PD. We sought...
2.
Hillmer A, Wooten D, Slesarev M, Ahlers E, Barnhart T, Schneider M, et al.
J Cereb Blood Flow Metab
. 2013 Aug;
33(11):1806-14.
PMID: 23942367
[(18)F]Nifene is an agonist PET radioligand developed to image α4β2* nicotinic acetylcholine receptors (nAChRs). This work aims to quantify the receptor density (Bmax) of α4β2* nAChRs and the in vivo...
3.
Wooten D, Hillmer A, Moirano J, Tudorascu D, Ahlers E, Slesarev M, et al.
Neuroimage
. 2013 Mar;
77:125-32.
PMID: 23537936
Unlabelled: Serotonin (5-HT) dysfunction has been implicated in neuropsychiatric illnesses and may play a pivotal role in the differential prevalence of depression between the sexes. Previous PET studies have revealed...
4.
Hillmer A, Wooten D, Slesarev M, Ahlers E, Barnhart T, Murali D, et al.
J Nucl Med
. 2012 Aug;
53(9):1471-80.
PMID: 22851633
Unlabelled: The PET radioligand 2-fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine ((18)F-nifene) is an α4β2* nicotinic acetylcholine receptor (nAChR) agonist developed to provide accelerated in vivo equilibrium compared with existing α4β2* radioligands. The goal of this...